Tolerogenic Nanoparticles to Treat Islet Autoimmunity

Tolerogenic Nanoparticles to Treat Islet Autoimmunity Curr Diab Rep (2017) 17:84 DOI 10.1007/s11892-017-0914-z PATHOGENESIS OF TYPE 1 DIABETES (A PUGLIESE, SECTION EDITOR) 1 1 Tobias Neef & Stephen D. Miller Springer Science+Business Media, LLC 2017 Abstract Introduction Purpose of Review The current standard therapy for type 1 diabetes (T1D) is insulin replacement. Autoimmune diseases Type 1 diabetes (T1D) is an autoimmune disease in which are typically treated with broad immunosuppression, but this cells of the immune system destroy the insulin-producing β has multiple disadvantages. Induction of antigen-specific tol- cells located in the pancreatic islets of Langerhans. Disease erance is preferable. The application of nanomedicine to the onset can occur at any time, but most often happens at 5– problem of T1D can take different forms, but one promising 7 years of age or puberty, and there are about 280 million cases way is the development of tolerogenic nanoparticles, the aim worldwide today [1, 2]. Currently, the most common therapy of which is to mitigate the islet-destroying autoimmunity. We for T1D is insulin replacement [1–3]. Unfortunately, insulin review the topic and highlight recent strategies to produce replacement is not without its drawbacks. The discomfort of tolerogenic nanoparticles for the purpose of treating T1D. subcutaneous injection and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Diabetes Reports Springer Journals

Tolerogenic Nanoparticles to Treat Islet Autoimmunity

Loading next page...
 
/lp/springer_journal/tolerogenic-nanoparticles-to-treat-islet-autoimmunity-biIoX0Izuq
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Diabetes
ISSN
1534-4827
eISSN
1539-0829
D.O.I.
10.1007/s11892-017-0914-z
Publisher site
See Article on Publisher Site

Abstract

Curr Diab Rep (2017) 17:84 DOI 10.1007/s11892-017-0914-z PATHOGENESIS OF TYPE 1 DIABETES (A PUGLIESE, SECTION EDITOR) 1 1 Tobias Neef & Stephen D. Miller Springer Science+Business Media, LLC 2017 Abstract Introduction Purpose of Review The current standard therapy for type 1 diabetes (T1D) is insulin replacement. Autoimmune diseases Type 1 diabetes (T1D) is an autoimmune disease in which are typically treated with broad immunosuppression, but this cells of the immune system destroy the insulin-producing β has multiple disadvantages. Induction of antigen-specific tol- cells located in the pancreatic islets of Langerhans. Disease erance is preferable. The application of nanomedicine to the onset can occur at any time, but most often happens at 5– problem of T1D can take different forms, but one promising 7 years of age or puberty, and there are about 280 million cases way is the development of tolerogenic nanoparticles, the aim worldwide today [1, 2]. Currently, the most common therapy of which is to mitigate the islet-destroying autoimmunity. We for T1D is insulin replacement [1–3]. Unfortunately, insulin review the topic and highlight recent strategies to produce replacement is not without its drawbacks. The discomfort of tolerogenic nanoparticles for the purpose of treating T1D. subcutaneous injection and

Journal

Current Diabetes ReportsSpringer Journals

Published: Aug 8, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off